alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
# C_2017103EN.01000301.xml

| 1.4.2017 | EN | Official Journal of the European Union | C 103/3 |
| --- | --- | --- | --- |

1.4.2017

EN

Official Journal of the European Union

C 103/3

---

Euro exchange rates (1)

1

31 March 2017

(2017/C 103/03)

1 euro =

1 euro =

| | Currency | Exchange rate |
| --- | --- | --- |
| USD | US dollar | 1,0691 |
| JPY | Japanese yen | 119,55 |
| DKK | Danish krone | 7,4379 |
| GBP | Pound sterling | 0,85553 |
| SEK | Swedish krona | 9,5322 |
| CHF | Swiss franc | 1,0696 |
| ISK | Iceland króna | |
| NOK | Norwegian krone | 9,1683 |
| BGN | Bulgarian lev | 1,9558 |
| CZK | Czech koruna | 27,030 |
| HUF | Hungarian forint | 307,62 |
| PLN | Polish zloty | 4,2265 |
| RON | Romanian leu | 4,5525 |
| TRY | Turkish lira | 3,8894 |
| AUD | Australian dollar | 1,3982 |
| CAD | Canadian dollar | 1,4265 |
| HKD | Hong Kong dollar | 8,3074 |
| NZD | New Zealand dollar | 1,5309 |
| SGD | Singapore dollar | 1,4940 |
| KRW | South Korean won | 1 194,54 |
| ZAR | South African rand | 14,2404 |
| CNY | Chinese yuan renminbi | 7,3642 |
| HRK | Croatian kuna | 7,4465 |
| IDR | Indonesian rupiah | 14 237,94 |
| MYR | Malaysian ringgit | 4,7313 |
| PHP | Philippine peso | 53,658 |
| RUB | Russian rouble | 60,3130 |
| THB | Thai baht | 36,724 |
| BRL | Brazilian real | 3,3800 |
| MXN | Mexican peso | 20,0175 |
| INR | Indian rupee | 69,3965 |

Currency

Exchange rate

USD

US dollar

1,0691

JPY

Japanese yen

119,55

DKK

Danish krone

7,4379

GBP

Pound sterling

0,85553

SEK

Swedish krona

9,5322

CHF

Swiss franc

1,0696

ISK

Iceland króna

NOK

Norwegian krone

9,1683

BGN

Bulgarian lev

1,9558

CZK

Czech koruna

27,030

HUF

Hungarian forint

307,62

PLN

Polish zloty

4,2265

RON

Romanian leu

4,5525

TRY

Turkish lira

3,8894

AUD

Australian dollar

1,3982

CAD

Canadian dollar

1,4265

HKD

Hong Kong dollar

8,3074

NZD

New Zealand dollar

1,5309

SGD

Singapore dollar

1,4940

KRW

South Korean won

1 194,54

ZAR

South African rand

14,2404

CNY

Chinese yuan renminbi

7,3642

HRK

Croatian kuna

7,4465

IDR

Indonesian rupiah

14 237,94

MYR

Malaysian ringgit

4,7313

PHP

Philippine peso

53,658

RUB

Russian rouble

60,3130

THB

Thai baht

36,724

BRL

Brazilian real

3,3800

MXN

Mexican peso

20,0175

INR

Indian rupee

69,3965

---

(1)  Source: reference exchange rate published by the ECB.

1

Source

---
U.S. Dept Commerce/NOAA/NMFS/NWFSC/Publications NOAA-NWFSC Tech Memo-4: National Benthic Surveillance Project: Northeast Coast Figures Figure 1. Map of East Coast showing sampling sites.  Figure 2. General shape of logistic function, p=1/(1 + e-x). Adapted from Schlesselman (1982). Figure 3. Taxonomic composition (% by weight) of stomach contents of winter flounder from selected East Coast sampline sites. Samples were collected during Cycle 5 (1988). Site abbreviations are defined in Table 1. Figure 4. Prevalences of hepatic lesions in winter flounder from the northern East Coast. Asterisk (*) indicates prevalence is significantly higher (G-statistic, p<0.05) than prevalence at Rocky Point reference site in Long Island Sound. FCA=foci of cellular alteration. Site abbreviations are defined in Table 1. For actual prevalence values, see Appendix Table A-3. Figure 5. Prevalences of hepatic lesions in winter flounder from the southern East Coast. Asterisk (*) indicates prevalence is significantly higher (G-statistic, p<0.05) than prevalence at Rocky Point reference site in Long Island Sound. FCA=foci of cellular alteration. Site abbreviations are defined in Table 1. For actual prevalence values, see Appendix Table A-3. Figure 6. Prevalences of kidney lesions in winter flounder from the East Coast. Asterisk (*) indicates prevalence is significantly higher (G-statistic, p<0.05) than prevalence at Rocky Point reference site in Long Island Sound. Site abbreviations are defined in Table 1. For actual prevalence values, see Appendix Table A-4. Figure 7. Prevalences of fin erosion in winter flounder from the East Coast. Asterisk (*) indicates prevalence is significantly higher (G-statistic, p<0.05) than prevalence at Rocky Point reference site in Long Island Sound (in italics). Site abbreviations are defined in Table 1. For actual prevalence values, see Appendix Table A-5. Table of Contents
#### 225.902 Procedures.

Follow the entry and release procedures at PGI 225.902.

[70 FR 73155, Dec. 9, 2005]
#### Mardan Construction Corporation, Respondent, v. Rogers Auto Sales Corp. et al., Appellants, et al., Defendant.

In an action to foreclose a mechanic’s lien and for a judgment against defendant Irving Rogers, individually, on his personal guarantee, the defendants, other than the defendant Levitt, appeal from an order of the Supreme Court, Queens County, dated April 2, 1959, which granted plaintiff’s motions and which: (a) struck out as sham certain allegations and defenses in the answers of said defendants, and (b) dismissed all the defenses and counterclaims in said answers for patent insufficiency, with leave to replead. The single order was entered on two motions made by plaintiff. Order reversed, with $19 costs and disbursements, and motions denied. On this record, we believe it was an improvident exercise of discretion to strike out the attacked allegations and defenses as sham. We also believe that all the attacked defenses and counterclaims are sufficient on their face. Nolan, P. J., Beldock, Ughetta and Kleinfeld, JJ., concur; Brennan, J., not voting. [18 Misc 2d 767.]
# C_2017154EN.01000102.xml

| 17.5.2017 | EN | Official Journal of the European Union | C 154/1 |
| --- | --- | --- | --- |

17.5.2017

EN

Official Journal of the European Union

C 154/1

---

Non-opposition to a notified concentration

(Case M.8418 — Peter Cremer Holding/Hage/König Transportgesellschaft)

(Text with EEA relevance)

(2017/C 154/02)

On 3 May 2017, the Commission decided not to oppose the above notified concentration and to declare it compatible with the internal market. This decision is based on Article 6(1)(b) of Council Regulation (EC) No 139/2004 (1). The full text of the decision is available only in German language and will be made public after it is cleared of any business secrets it may contain. It will be available:

1

| — | in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes, |
| --- | --- |

—

in the merger section of the Competition website of the Commission (http://ec.europa.eu/competition/mergers/cases/). This website provides various facilities to help locate individual merger decisions, including company, case number, date and sectoral indexes,

| — | in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32017M8418. EUR-Lex is the online access to the European law. |
| --- | --- |

—

in electronic form on the EUR-Lex website (http://eur-lex.europa.eu/homepage.html?locale=en) under document number 32017M8418. EUR-Lex is the online access to the European law.

---

(1)  OJ L 24, 29.1.2004, p. 1.

1

---
Exhibit 31.1


                                 Certifications

I, Simon K. Gill, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Chaparral Resources,
Inc.;

2. Based on my knowledge, this quarterly report does not contain any untrue
statement of a material fact or omit to state a material fact necessary to make
the statements made, in light of the circumstances under which such statements
were made, not misleading with respect to the period covered by this quarterly
report;

3. Based on my knowledge, the financial statements, and other financial
information included in this quarterly report, fairly present in all material
respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this quarterly report;

4. The registrant's other certifying officers and I are responsible for
establishing and maintaining disclosure controls and procedures (as defined in
Exchange Act Rules 13a-15(e) and 15d-15(e) for the registrant and we have:

     a) designed such disclosure controls and procedures to ensure that material
     information relating to the registrant, including its consolidated
     subsidiaries, is made known to us by others within those entities,
     particularly during the period in which this quarterly report is being
     prepared;

     b) evaluated the effectiveness of the registrant's disclosure controls and
     procedures as of a date within 90 days prior to the filing date of this
     quarterly report (the "Evaluation Date"); and

     c) presented in this quarterly report our conclusions about the
     effectiveness of the disclosure controls and procedures based on our
     evaluation as of the Evaluation Date;

5. The registrant's other certifying officers and I have disclosed, based on our
most recent evaluation, to the registrant's auditors and the audit committee of
registrant's board of directors (or persons performing the equivalent function):

     a) all significant deficiencies in the design or operation of internal
     controls which could adversely affect the registrant's ability to record,
     process, summarize and report financial data and have identified for the
     registrant's auditors any material weaknesses in internal controls; and

     b) any fraud, whether or not material, that involves management or other
     employees who have a significant role in the registrant's internal
     controls; and

6. The registrant's other certifying officers and I have indicated in this
quarterly report whether or not there were significant changes in internal
controls or in other factors that could significantly affect internal controls
subsequent to the date of our most recent evaluation, including any corrective
actions with regard to significant deficiencies and material weaknesses.



Date: November 11, 2004




/s/  Simon K. Gill
-----------------------
Simon K. Gill
Chief Executive Officer
Executive Order 13982

# Care of Veterans With Service in Uzbekistan

By the authority vested in me as President by the Constitution and the laws of the United States of America, it is hereby ordered as follows:

**Section 1**                    . The Secretary of Veterans Affairs, in consultation with the Secretary of Defense, shall consider whether to designate veterans who served on active duty in Uzbekistan between October 1, 2001, and December 31, 2005, as veterans who served on active duty in a theater of combat operations pursuant to section 1710(e)(1)(D) of title 38, United States Code.                

**Sec. 2**                    . Within 365 days of the date of this order, the Secretary of Defense shall conduct a rigorous study investigating toxic exposure by members of the Armed Forces deployed to the Karshi-Khanabad Air Base, Uzbekistan (Air Base), between October 1, 2001, and December 31, 2005. The Secretary of Defense shall submit a report summarizing the findings of the study to the President, through the Secretary of Veterans Affairs. The study shall include the following elements:                

(a) A detailed assessment of the conditions at the Air Base between October 1, 2001, and December 31, 2005, including identification of any toxic substances contaminating the Air Base during such period, the exact locations of the toxic substances, the time frames of exposure to the toxic substances, the service members exposed to the toxic substances, and the circumstances of such exposure.

(b) A rigorous epidemiological study of any health consequences for members of the Armed Forces deployed to the Air Base between October 1, 2001, and December 31, 2005. This study shall be of equivalent rigor to studies used by the Department of Veterans Affairs to make determinations regarding diseases subject to presumptive service connections.

(c) An assessment of any causal link between exposure to any toxic substances identified in subsection (a) of this section and any health consequences studied under subsection (b) of this section.

**Sec. 3**                    .                     *General Provisions.*                     (a) Nothing in this order shall be construed to impair or otherwise affect:                

(i) the authority granted by law to an executive department or agency, or the head thereof; or

(ii) the functions of the Director of the Office of Management and Budget related to budgetary, administrative, or legislative proposals.

(b) This order shall be implemented in a manner consistent with applicable law and subject to the availability of appropriations.

(c) This order is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.

[FR Doc. 2021-01712

Billing code 3295-F1-P
26.300 Scope of subpart. ( a ) This subpart implements Executive Order 12928 of September 16, 1994, which promotes participation of Historically Black Colleges and Universities (HBCUs) and Minority Institutions (MIs) in Federal procurement.
( b ) This subpart does not pertain to contracts performed entirely outside the United States and its outlying areas.
[62 FR 12703, Mar. 17, 1997, as amended at 68 FR 28083, May 22, 2003]
Exhibit 32.1



CERTIFICATION PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(18 U.S.C. SECTION 1350)



In connection with the Amendment No. 2 to the Annual Report of Flow
International Corporation, a Washington corporation (the Company), on Form 10-K/A for the year ending April 30, 2005 as filed with the Securities and Exchange Commission (the Report), I, Stephen R. Light, Principal
Executive Officer of the Company, certify, pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350), that to my knowledge:



(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2) The information contained in the Report fairly
presents, in all material respects, the financial condition and result of operations of the Company.



|                                                             
|-------------------------------------------------------------
|/s/    STEPHEN R.
LIGHT                                      
|Stephen R. Light Principal Executive Officer January 31, 2006
225.872-5 Contract administration. ( a ) Arrangements exist with some qualifying countries to provide reciprocal contract administration services. Some arrangements are at no cost to either government. To determine whether such an arrangement has been negotiated and what contract administration functions are covered, contact the Office of the Principal Director, Defense Pricing, Contracting, and Acquisition Policy (Contract Policy) via email at *osd.pentagon.ousd-a-s.mbx.asda-dp-c-contractpolicy@mail.mil .*
( b ) Follow the contract administration procedures at PGI 225.872-5(b).
( c ) Information on quality assurance delegations to foreign governments is in Subpart 246.4, Government Contract Quality Assurance.
[68 FR 15621, Mar. 31, 2003, as amended at 70 FR 73155, Dec. 9, 2005; 72 FR 30278, May 31, 2007; 88 FR 73237, Oct. 25, 2023; 89 FR 60831, July 29, 2024]
Full Document PDF (17.38M)

Message From the Secretary PDF (553K)

**Management's Discussion and Analysis**PDF (4M)

- About the Management's Discussion and Analysis/About the Department    PDF (280K)
- The Department’s Approach to Performance    PDF (301K)
- Financial Highlights    PDF (362K)
- Management Assurances/Analysis of Systems, Controls, and Legal Compliance    PDF (235K)
- Forward-Looking Information    PDF (215K)

**Financial Section**PDF (2M)

- Financial Statements    PDF (208K)
- Notes to Financial Statements    PDF (463K)
- Required Supplementary Information    PDF (230K)
- Required Supplementary Stewardship Information    PDF (220K)
- Report of the Independent Auditors    PDF (952K)

**Other Information**PDF (1.4M)

- Office of the Inspector General’s Management and Performance Challenges for Fiscal Year 2019   PDF (226K)
- Summary of Financial Statement Audit and Management Assurances    PDF (212K)
- Payment Integrity    PDF (311K)
- Fraud Reduction Report    PDF (191K)
- Reduce the Footprint    PDF (200K)
- Civil Monetary Penalty Adjustment for Inflation    PDF (239K)
- GONE Act Information    PDF (194K)
- Other Reporting    PDF (912K)

**Appendices**PDF (2M)

| Properties: | Title: U.S. Department of Education FY 2016  Agency Financial Report          |
|-------------|-------------------------------------------------------------------------------|
|        | Author:  U.S.  Department of Education, Office of the Chief Financial Officer |
#### UNITED STATES of America, Plaintiff-Appellee, v. Francisco DEL SOL, Raul Torres Claro and Angel Luis Reyes Molina, Defendants-Appellants.

No. 81-5761

Non-Argument Calendar.

United States Court of Appeals, Eleventh Circuit.

June 21, 1982.

*217Cohen, Kokus & Ostrow, George A. Kokus, Miami, Fla., for defendants-appellants.

Stanley Marcus, U. S. Atty., Miami, Fla., for plaintiff-appellee.

Before GOLDBERG*, HILL and HATCHETT, Circuit Judges.

*

 Honorable Irving L. Goldberg, U. S. Circuit Judge for the Fifth Circuit, sitting by designation.

PER CURIAM:

During a safety and documents check, officers of the United States Coast Guard discovered approximately 12,000 pounds of marijuana aboard the appellants’ fishing vessel, which was anchored off the coast of the Bahamas. The appellants, all of whom are foreign nationals, pled guilty to charges of knowingly possessing with the intent to distribute a controlled substance in violation of 21 U.S.C. § 955a(a) and 18 U.S.C. § 2. The issue they raise on appeal is whether the district court had jurisdiction absent an allegation and proof by the government that they intended to affect the United States in any way.

Recent decisions of this court lead us to conclude without hesitation that “law of the flag” jurisdiction existed in this case. In passing § 955a, Congress intended to reach extraterritorial acts of possession aboard American ships under that theory of jurisdiction. *United States v. Riker,*670 F.2d 987 (11th Cir. 1982). Here, the indictment alleged that the vessel in question was “a vessel of the United States,” and the appellants do not contend otherwise. There is a dispute as to whether the vessel was on the high seas or within the territorial waters of the Bahamas, but that issue is irrelevant. “Under well established principles of international law, the jurisdiction of the United States to prosecute crimes on board ship is concurrent with the jurisdiction of the nation in whose waters the crime occurs.” *United States v. Liles,*670 F.2d 989, 992 (11th Cir. 1982).

The convictions are

AFFIRMED.
[Federal Register Volume 86, Number 11 (Tuesday, January 19, 2021)]
[Notices]
[Page 5224]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2021-01047]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Center for Advancing Translational Sciences; Notice of 
Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The contract proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the contract proposals, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Advancing Translational 
Sciences Special Emphasis Panel; SBIR PHASE I, Topic 021.
    Date: February 2, 2021.
    Time: 10:00 a.m. to 6:00 p.m.
    Agenda: To review and evaluate contract proposals.
    Place: National Center for Advancing Translational Sciences, 
National Institutes of Health, 6701 Democracy Boulevard, Room 1080, 
Bethesda, MD 20892-4878 (Virtual Meeting).
    Contact Person: Victor Henriquez, Ph.D., Scientific Review 
Officer, Office of Scientific Director, National Center for 
Advancing Translational Sciences, National Institutes of Health, 
6701 Democracy Boulevard, Room 1080, Bethesda, MD 20892-4878, 301-
435-0813, <a href="/cdn-cgi/l/email-protection#3a525f5448534b4f4c7a575b535614545352145d554c"><span class="__cf_email__" data-cfemail="7a121f1408130b0f0c3a171b131654141312541d150c">[email protected]</span></a>.

    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, 
Pharmacology, Physiology, and Biological Chemistry Research; 93.350, 
B--Cooperative Agreements; 93.859, Biomedical Research and Research 
Training, National Institutes of Health, HHS)

    Dated: January 12, 2021.
David W. Freeman,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2021-01047 Filed 1-15-21; 8:45 am]
BILLING CODE 4140-01-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>